Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travoprost vs Latanoprost in Chronic Angle-Closure Glaucoma
NCT00051181Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jan 2000
- Primary completion
- Jun 2003
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of travoprost in chronic angle-closure glaucoma (CACG), sponsored by Alcon Inc.. Started Jan 2000; status: completed.
02
Drugs
travoprost
03
Conditions
chronic angle-closure glaucoma (CACG)
Beyond the preview
Go deeper on NCT00051181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051181.